Scientists are exploring localized treatment in follicular lymphoma (FL) using dendritic cells that could have long-range benefits on all FL lesions.
B cells orchestrate mutations on cue. The procedure for antibody development requires a second take to get the performance right.
Although glatiramer acetate has been around for about 20 years, we still do not have the full picture of its mode of action, especially on B cells.
Scientists have shown that trichostatin A could be a potent apoptosis inducer to target chronic lymphocytic leukemia cells.